Picard Medical (PMI) announced the strengthening of its intellectual property portfolio with the recent grant of U.S. Patent No. 12,383,722 B2 covering systems and methods related to its next-generation SynCardia Total Artificial Heart, the “Emperor.” This recently granted patent, relating to the apparatus, systems, and methods for enabling a next-generation total artificial heart which provides enhanced patient flexibility, builds on earlier grants U.S. Patent No. 11,918,798 B2 and U.S. Patent No. 12,121,711 B2, bringing the Company’s total number of patented claims in the United States to 34 covering its next-generation total artificial heart system. In addition, the Company holds China Patent No. 115279450 B, which extends similar protection for the fully implantable platform in that jurisdiction. The Emperor is expected to be fully implantable and provide pulsatile flow without requiring an external pneumatic driver.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMI:
- Picard Medical Reports Increased Losses Amid Rising Revenues
- Picard Medical reports Q2 revenue $2.131M vs $694k last year
- Picard Medical Completes Successful IPO, Raises $19.55 Million
- Picard Medical appoints Sam Van, George Ye to board of directors
- Picard Medical Completes Successful IPO Raising $17 Million